Intrinsiqq
Gossamer Bio Inc. logo

Gossamer Bio Inc. Intrinsic Value

GOSS

⊜ Compare

Choose a model

Each card values Gossamer Bio a different way, shown at our starting inputs. Pick one to see and change how it works.

Set your assumptions

Gossamer Bio on revenue: sales per share grow and the stock trades at a normal price-to-sales multiple. For companies not yet profitable.

Years to project

Growth of revenue per share

Revenue per share; not enough history; starts at 5%

Exit P/S

Starts at its industry's median P/S

Your desired return

Margin of safety

More

Your buy price

The expected return is measured from it; starts at today's price

How it's worked out

  1. Today's revenue per share

    Last twelve months

    $0.11

  2. Revenue in 2031

    Grows 5.0% a year for 5 years

    $0.14

  3. Price in 2031

    $0.14 × 3.2 P/S

    $0.45

  4. Worth today

    ÷ 1.10^5: your 10% a year, taken back out

    $0.28

  5. Fair value

    The most you can pay and still earn 10% a year

    $0.28

  6. Buy below

    Fair value minus your 25% margin of safety

    $0.21

Paying $9.40 instead gives -45.7% a year. Every rule is on the methodology page.

Outcome

What your assumptions give, and the path from today's price.

Fair value

$0.28

Expected return

-45.7% a year

Future price, 2031

$0.45

Buy below

$0.21

Price 3301% above fair valuePrice $9.40, at your 10% return

Projection

Solid blue: the price at each year end. Dashed blue: from today's price to the 2031 price. Green: from the fair value, rising at your 10% a year to the same end point; buy at or below it and you earn at least that. Every rule is on the methodology page. A model, not a forecast or advice.

Gossamer Bio (GOSS) intrinsic value and fair value

The calculator grows one of Gossamer Bio's per-share figures (earnings, free cash flow, revenue, book value or dividends) for a few years, puts an exit multiple on it, and discounts the result back at the yearly return you want. The answers below use its starting inputs for GOSS; this is analysis, not investment advice.

Frequently asked

What is Gossamer Bio's (GOSS) intrinsic value?+

With Intrinsiqq's starting inputs, Gossamer Bio's fair value is about $0.28 a share, based on its revenue per share. That assumes revenue per share of $0.11 grows about 5.0% a year for 5 years, the stock then trades at 3.2 times revenue, and you want a 10.0% yearly return. Every input can be changed on the page; the result is a model, not a forecast.

Is Gossamer Bio overvalued?+

At $9.40, the price is 3301% above that fair value of $0.28, and buying at today's price would return about -45.7% a year if those inputs hold. Whether that is cheap or dear depends on whether you believe the growth and the exit multiple, which is what the calculator lets you test. This is analysis from SEC filings, not investment advice.

What growth does the Gossamer Bio valuation assume?+

Revenue per share grows about 5.0% a year to start, a default, because there is too little history. The exit multiple starts at its industry's median.

What is a good margin of safety for Gossamer Bio?+

A margin of safety is the cushion you want below the fair value before buying, in case the inputs are wrong. The calculator uses 25%, which puts the buy-below price at $0.21. Less predictable businesses deserve a wider cushion, or a higher desired return.

How the market compares: US profitability statistics

Peers

Pharmaceutical Preparations · Pick stocks to compare with GOSS

CompareIntrinsic value
QTTBQ32 Bio Inc.
$8.97+2.40%60
TNGXTango Therapeutics Inc.
$23.18+0.04%40
CARMCarisma Therapeutics Inc.
$0.00+100.00%60
AQSTAquestive Therapeutics Inc.
$3.80-2.06%10
OCULOcular Therapeutix Inc.
$7.14+4.69%10
NKTRNektar Therapeutics Inc.
$38.48+1.91%25
AYTUAytu BioPharma Inc.
$1.92-0.52%48
PRTAProthena Corporation plc
$8.39+2.19%25

Held by ETFs

GOSS is in 5 US ETFs. The largest of them, with GOSS's weight in each:

Spot a number that looks wrong? Check it in GOSS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GOSS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.